With drug-resistant bacteria on the rise, antibiotics have struggled to keep up. But with an FDA nod for Nabriva's Xenleta, some of that may change.

JAK drugs have run into safety issues, and if the label for AbbVie's Rinvoq is any indication, the FDA now believes those the issues are class-wide.

And the winner is Publicis Groupe. Novartis has selected the agency to handle its global media account under a newly created group, NovartisONE2.

Amarin may still be waiting for the FDA to include new risk-reduction info to Vascepa's label, but in the meantime, it's getting prepared.

Consumers love to hate Reckitt Benckiser's Mr. Mucus, according to a new study.

More than one-fourth of all top-10 pharma TV spending in July came from one brand—AbbVie's Humira.

Consultancy ZS recently launched an editorial series called "AI &" to dive into artificial intelligence best practices for pharma.

In December, J&J touted head-to-head results for Tremfya against Novartis’ Cosentyx. But now, Lilly has topped Tremfya in a contest of its own.